RNAZ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (16 Apr 2024 @ 15:03):

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease...

Stats
Today's Volume	383 612
Average Volume	712 982
Market Cap	3.32M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.700 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0.00300 (0.59%)

Insider Trading

Date	Person	Action	Amount	type
2023-09-28	Fitzgerald Thomas A	Buy	49 350	Common Stock
2023-09-28	Dudley Robert Michael	Buy	98 000	Common Stock
2023-06-21	Dudley Robert Michael	Buy	12 000	Common Stock
2023-06-20	Dudley Robert Michael	Buy	6 607	Common Stock
2023-06-09	Dudley Robert Michael	Buy	19 000	Common Stock

INSIDER POWER
100.00
Last 36 transactions
Buy: 2 048 457 \| Sell: 1 170 653

Volume Correlation

Long: 0.03 (neutral)

Short: -0.26 (neutral)

Signal:(45.831) Neutral

TransCode Therapeutics, Correlation

10 Most Positive Correlations
APOP	0.933
MAGS	0.88
CMLF	0.856
RMRM	0.838

10 Most Negative Correlations
MXIM	-0.807
MMAC	-0.805
WLTW	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

TransCode Therapeutics, Correlation - Currency/Commodity

-0.73
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

0.71
( moderate )

TransCode Therapeutics, Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-516 746 (0.00 %)
EPS:	$-103.61

Q4	2023
Revenue:	$0
Gross Profit:	$-140 173 (0.00 %)
EPS:	$-6.51

Q3	2023
Revenue:	$0
Gross Profit:	$-138 783 (0.00 %)
EPS:	$-67.15

Q2	2023
Revenue:	$0
Gross Profit:	$-137 591 (0.00 %)
EPS:	$-131.61

Financial Reports:

No articles found.

TransCode Therapeutics,

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNAbased agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.